SimBioSys and Ferrum Health Partner to Expand Access to FDA-Cleared AI Surgical Planning Platform for Breast Cancer
核心洞察
SimBioSys (搜索) and Ferrum Health (搜索) announced a strategic partnership to make the FDA-cleared TumorSight Viz (搜索) platform available through Ferrum's Model Hub for enterprise-wide deployment.
TumorSight Viz (搜索) transforms standard breast MRI into interactive, patient-specific 3D visualizations, providing surgeons with deeper anatomical insight for individualized surgical planning.
The collaboration enables health systems to deploy, manage, and scale AI-driven surgical planning capabilities within a trusted, enterprise-grade infrastructure with centralized oversight and performance monitoring.
SimBioSys (搜索), an AI-driven precision medicine company focused on transforming cancer care, announced on July 23, 2026 a strategic partnership with Ferrum Health (搜索) to make its FDA-cleared TumorSight Viz (搜索) platform available through Ferrum's Model Hub. The collaboration, unveiled in Chicago, aims to enable health systems nationwide to more seamlessly deploy, manage, and scale AI-powered surgical planning capabilities within an enterprise-grade infrastructure.
The partnership addresses a critical need in clinical AI adoption: bridging the gap between innovation and practical implementation within complex health system environments.
TumorSight Viz (搜索): AI-Powered 3D Surgical Planning
TumorSight Viz (搜索) is an FDA-cleared AI-powered platform that converts standard breast MRI into interactive, patient-specific 3D visualizations. The technology provides surgeons with deeper anatomical insight to support more informed and individualized surgical planning for breast cancer (搜索) patients. By transforming conventional imaging into decision-driving intelligence, the platform aims to deliver greater confidence, precision, and personalization in cancer treatment.
SimBioSys (搜索) is also developing TumorSight Risk, a complementary solution that combines AI and spatial biophysics, though this product remains in development.
Enterprise Integration Through Ferrum's Model Hub
Ferrum Health (搜索)'s Model Hub enables health systems to deploy and manage AI applications at scale, providing centralized oversight, model monitoring, and integration across clinical environments. The vendor-neutral suite validates and monitors clinical AI models within a health system's owned, secure environment, allowing organizations to deploy models faster, validate performance objectively, and maintain complete visibility across their AI portfolio.
Through this integration, TumorSight Viz (搜索) can be delivered within existing health system infrastructure, enabling streamlined deployment, performance monitoring, and enterprise-wide scalability.
"Bringing AI into clinical practice requires more than innovation—it requires practical implementation within health systems," said Stacey Stevens, President and CEO of SimBioSys (搜索). "As we expand access to TumorSight Viz (搜索), our focus is on delivering clinically validated solutions that integrate seamlessly into real-world care environments. Partnering with Ferrum enables us to bring our AI-driven surgical planning platform to more institutions—supporting more informed decision-making while maintaining high standards of performance and reliability."
Pelu Tran, CEO of Ferrum Health (搜索), emphasized the clinical significance of the addition: "TumorSight Viz (搜索) brings a new dimension to our platform in breast surgical planning—an area where precision and context are critical. By embedding patient-specific surgical insight within our broader clinical AI portfolio, our partnership with SimBioSys (搜索) expands the scope of intelligence we can deliver across the care continuum."
Clinical Adoption and Scale
TumorSight Viz (搜索) is currently in use across leading clinical and research institutions and continues to demonstrate strong performance in delivering reproducible, anatomy-specific insight to support surgical planning. Through this collaboration, SimBioSys (搜索) and Ferrum aim to further accelerate access to these capabilities across a broader network of health systems.
Ferrum Health (搜索) is backed by $31 million in funding, including a Series A led by Foundry, and serves over 350 care sites globally. The addition of TumorSight Viz (搜索) expands Ferrum's portfolio of clinically validated AI solutions supporting imaging, diagnostics, and care delivery.